Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy.
| Autor: | Kadia TM; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kantarjian HM; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Konopleva M; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Oncotarget [Oncotarget] 2019 Feb 08; Vol. 10 (12), pp. 1250-1265. Date of Electronic Publication: 2019 Feb 08 (Print Publication: 2019). |
| DOI: | 10.18632/oncotarget.26579 |
| Abstrakt: | Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, affecting approximately 21,000 people annually (nearly 11,000 deaths) in the United States. B-cell lymphoma 2 (BCL-2) family proteins, notably myeloid cell leukemia-1 (MCL-1), have been associated with both the development and persistence of AML. MCL-1 is one of the predominant BCL-2 family members expressed in samples from patients with untreated AML. MCL-1 is a critical cell survival factor for cancer and contributes to chemotherapy resistance by directly affecting cell death pathways. Here, we review the role of MCL-1 in AML and the mechanisms by which the potent cyclin-dependent kinase 9 inhibitor alvocidib, through regulation of MCL-1, may serve as a rational therapeutic approach against the disease. Competing Interests: CONFLICTS OF INTEREST Tapan Mahendra Kadia: Consultant for AbbVie, Amgen, Jazz Pharmaceuticals, Genentech, Novartis, and Takeda; research funding from AbbVie, Bristol-Myers Squibb, Celgene, Jazz Pharmaceuticals, Pfizer, and Sanofi. Hagop M. Kantarjian: Honoraria from AbbVie, Agios, Amgen, Immunogen, Orsinex, Pfizer, and Takeda; research funding from AbbVie, Agios, Amgen, Ariad, Astex, Bristol-Myers Squibb, Cyclacel, Imunogen, Jazz Pharmaceuticals, and Pfizer. Marina Konopleva: Consultant for AbbVie, Genentech, F. Hoffman La-Roche; served as advisory board member for F. Hoffman La-Roche; holds shares from Reata Pharmaceuticals; honoraria from Amgen, Abbvie, and Genentech; research funding from AbbVie, Genentech, Eli Lilly, Cellectis, Calithera, Stemline, Threshold, Flexus Biosciences, Novartis, Ablynx, and Agios. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|